Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment

INTRODUCTION: Type 2 diabetes (T2D) is the leading cause of chronic kidney disease (CKD). The recommended dose of the dipeptidyl peptidase-4 inhibitor saxagliptin is 2.5 mg in patients with moderate or severe renal impairment (creatinine clearance ≤50 mL/min). In this post hoc analysis, we assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Perl, Shira, Cook, William, Wei, Cheryl, Iqbal, Nayyar, Hirshberg, Boaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014790/
https://www.ncbi.nlm.nih.gov/pubmed/27402391
http://dx.doi.org/10.1007/s13300-016-0184-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014790/
https://www.ncbi.nlm.nih.gov/pubmed/27402391
http://dx.doi.org/10.1007/s13300-016-0184-9

Ejemplares similares